Abstract
The ideal vaccine is one that is stable, safe, administered orally in a single dose at birth, 100% effective, reasonably priced, and protective for a lifetime. Unfortunately, there is no such vaccine (Dowdle and Orenstein, 1995). The development of vaccines has been one of the most important achievements in immunology and medicine. The existing vaccines, which consist mostly of killed or live attenuated microbial agents or their isolated components, have led to the eradication of smallpox and have diminished the incidence, morbidity and mortality in a large number of infectious diseases, including polio, measles and diphtheria. The current procedures of vaccines preparation present, nevertheless, problems such as whether a particular viral vaccine preparation is completely killed or sufficiently attenuated, the difficulty in preparing enough material for vaccine production, and the genetic variation in viruses.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Anderer, F.A., 1963, Preparation and properties of an artificial antigen immunologically related to tobacco mosaic virus. Biochim. Biophys. Acta 71:246–248.
Arnon, R., 1972, Synthetic vaccines-dream or reality. In “Immunity and viral and rickettsial diseases,” eds. A. Kohn and A.M. Klingberg, Plenum Press, New York, pp. 209–222.
Arnon, R., 1986, Synthetic peptides as the basis for future vaccines. TIBS 11:521–524.
Arnon, R., Maron, E., Sela, M., and Anfinsen, C.B., 1971, Antibodies reactive with native lysozyme elicited by a completely synthetic antigen. Proc. Natl. Acad. Sci. USA 68:1450–1454.
Arnon, R., Sela, M., Parant, M., and Chedid, L., 1980, Antiviral response elicited by a completely synthetic antigen with built-in adjuvanticity. Proc. Natl. Acad. Sci. USA 77:6769–6772.
Audibert, F., Jolivet, M., Chedid, L., Alouf, J.E., Bouquet, P., Rivaille, P., and Siffret, O., 1981, Active antitoxic immunization by a diphtheria toxin synthetic oligopeptide. Nature 289:593–595.
Audibert, F., Jolivet, M., Chedid, L., Amon, R., and Sela, M. 1982, Successful immunization with a totally synthetic diphtheria vaccine. Proc. Natl Acad. Sci. USA 79:5042–5046.
Brocke, S., Brautbar, C., Steinman, L., Abramsky, O., Rothbard, J., Neumann, D., Fuchs, S., and Mozes, E., 1988, In vitro proliferative responses and antibody titers specific to human acetylcholine receptor synthetic peptides in patients with myasthenia grais and relation to HLA class II genes. J. Clin. Invest. 82:1894–1900.
Brocke, S., Dayan, M., Rothbard, J., Fuchs, S., and Mozes, E., 1990, The autoimmune response of different mouse strains to T-cell epitopes of the human acetylcholine receptor alpha subunit. Immunology 69:495–500.
Dowdle, W.R., and Orenstein, W.A., 1995, Quest for life-long protection by vaccination. In “Infectious diseases in an age of change”, ed B. Roizman, National Academy of Sciences, Washington, D.C., pp. 235–247.
Fridkis-Hareli, M., Teitelbaum, D., Gurevich, E., Pecht, I., Brautbar, C., Kwon, O.J., Brenner, T., Arnon, R., and Sela, M., 1994, Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells-specificity and promiscuity. Proc. Natl. Acad. Sci. USA 91:4872–4876.
Jacob, CO., Arnon, R., and Sela, M., 1986, Anti-cholera response elicited by a completely synthetic antigen with built-in adjuvanticity administered in aqueous solution. Immunol. Lett. 14:43–48.
Jacob, CO., Sela, M., and Arnon, R., 1983, Antibodies against synthetic peptides of the B subunit of cholera toxin: cross-reaction and neutralization of the toxin. Proc. Natl. Acad. Sci. USA 80, 7611–7615.
Katz-Levy, Y, Kirshner, S.L., Sela, M., and Mozes, E., 1993, Inhibition of T cell reactivity to myasthenogenic epitopes of the human acetylcholine receptor by synthetic analogs. Proc. Natl. Acad. Sci. USA 90:7000–7004.
Langbeheim, H., Arnon, R., and Sela, M., 1976, Antiviral effect on MS-2 coliphage obtained with a synthetic antigen. Proc. Natl. Acad. Sci. USA 73:4636–4670.
Lindstrom, J., Shelton, D., and Fuji, Y., 1988, Myasthenia gravis. Adv. Immunol. 42:233–284.
Muller, G.M., Shapira, M., and Arnon, R., 1982, Anti-influenza response achieved by immunization with a synthetic conjugate. Proc. Natl. Acad. Sci. USA: 79:569–573.
Sakai, K., Zamwil, S.S., Mitchell, DJ., Hodgkinson, S., Rothbard, J.B., and Steinman, L., 1989, Prevention of experimental encephalomyelitis with peptides that block interaction of T cells with major histocompatibility complex antigens. Proc. Natl. Acad. Sci. USA 86:9470–9474.
Sela, M., 1974, Vaccins synthetiques-un reve ou une realite? Bull. Inst. Pasteur 72:73–86.
Sela, M., and Arnon, R., 1992, Synthetic approaches to vaccines for infectious and autoimmune diseases. Vaccine 10:991–999.
Teitelbaum, D., Aharoni, R., Arnon, R., and Sela, M., 1988, Specific inhibition of the T cell response to myelin basic protein by the suppressive copolymer COP 1. Proc. Natl Acad. Sci. USA 85:9724–9728.
Teitelbaum, D., Milo, R., Arnon, R., and Sela, M., 1992, Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein. Proc. Natl Acad. Sci. USA 89:137–141.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer Science+Business Media New York
About this chapter
Cite this chapter
Sela, M. (1996). Synthetic Vaccines for Infectious and Autoimmune Diseases. In: Cohen, S., Shafferman, A. (eds) Novel Strategies in the Design and Production of Vaccines. Advances in Experimental Medicine and Biology, vol 397. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-1382-1_1
Download citation
DOI: https://doi.org/10.1007/978-1-4899-1382-1_1
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-1384-5
Online ISBN: 978-1-4899-1382-1
eBook Packages: Springer Book Archive